Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren’s Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction

The publication “Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren’s Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction” is organized in H2HUBB under the research focus molecular hydrogen exercise recovery study 2025. The publication is cited as TSAI YING-HSUAN, LU JENG-WEI, TU JOU-I, LI YUAN-JU, HSU HUI-FU, CHANG FENG-HAO, HO YI-JUNG, LUI SHAN-WEN, HSIEH TING-YU, WANG KUANG-YIH, LIU FENG-CHENG, In Vivo, 2025. This case report or case series examined Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren’s Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction. The abstract describes Human participants. The abstract reports: This case highlights the potential of molecular hydrogen (H) therapy as a safe, effective adjunct in managing overlapping Sjögren's syndrome, SLE, and ILD. H…. This is an automated editorial draft based on the abstract and requires source review before publication.

Molecular hydrogen exercise recovery study 2025 overview

Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) are chronic autoimmune diseases that often coexist. They share features such as systemic inflammation and multi-organ… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.

Study design and hydrogen intervention

Publication type: Case report or case series. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.

Delivery method: Other or not reported.

Reported findings and scientific interpretation

For this molecular hydrogen exercise recovery study 2025, the study record reports the following: The abstract reports: This case highlights the potential of molecular hydrogen (H) therapy as a safe, effective adjunct in managing overlapping Sjögren's syndrome, SLE, and ILD. H…

These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.

How this research record was prepared

H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.

Limitations, safety, and original source

Limitations: Case-report evidence cannot establish causality or broad generalizability.

Safety: The abstract did not provide detailed safety or adverse-event information.

This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.